Definition

An orally available inhibitor of tropomyosin receptor kinase (Trk), with potential antineoplastic activity. Upon oral administration, Trk inhibitor TQB3558 targets and binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation. This may lead to apoptosis of Trk-expressing tumor cells and the inhibition of tumor cell proliferation in Trk-expressing tumors. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.